driven by the FACS DiVa software package (BD Biosciences), and data were analyzed with FlowJo (Tree Star Inc., Ashland, OR).
Detection of plasma SIV RNA by standard RT-PCR assay. Plasma SIV loads were determined by standard quantitative RT-PCR as previously described (limit of detection, 60 copies/ml) (31) . Briefly, 150 l of plasma was used to extract viral SIV smm RNA by using a QIAamp viral RNA minikit (Qiagen, Valencia, CA). Ten microliters of extracted RNA was subjected to RT-PCR by using random hexamers to prime reverse transcription (Invitrogen, Carlsbad, CA). Primer and probe sequences were targeted to the 5=-untranslated region of the SIV smm genome (forward primer, 5=-GGCAGGAAAATCCCTAGCAG-3=; reverse primer, 5=-GCCCTTACTGCCTTCACTCA-3=; and probe, 5=-AGTCCCTGTTC RGGCGCCAA-3=) (4) . The SIV RNA copy number was determined by comparison to an external standard curve created with virion-derived SIV smm RNA. For graphical reasons, samples with SIV RNA levels below the detection limit of the assay were assigned a level of half the lower limit of detection.
SIV smm sequence analysis for primer development. In order to generate a specific and sensitive quantitative SIV smm real-time PCR assay, we sequenced the gag genes of the viruses present in all test animals prior to therapeutic intervention. The day Ϫ30 pre-ART plasma samples were utilized to assess overall sequence diversity in the cohort of naturally infected sooty mangabeys. Viral RNA was extracted from plasma by using a QIAamp viral RNA minikit (Qiagen). RNA was eluted and immediately subjected to cDNA synthesis. Reverse transcription of RNA to singlestranded cDNA was performed using SuperScript III according to the manufacturer's instructions (Invitrogen). Briefly, a 0.5 mM concentration of each deoxynucleoside triphosphate and 0.25 M antisense primer SIV-Gag-R1 (5=-TGACTACTGGTCTCCTCCAAAGAG-3=) were incubated at 65°C for 5 min and then moved to ice for 1 min. Next, 1ϫ RT buffer, 5 mM dithiothreitol, 2 U/l RNaseOUT, and 10 U/l SuperScript III reverse transcriptase were incubated at 50°C for 60 min, followed by an increase in temperature to 55°C for an additional 60 min. SuperScript III was then heat inactivated at 70°C for 15 min and treated with 2 U of RNase H at 37°C for 20 min. cDNA was used immediately for single genome amplification (SGA) PCR. Briefly, 1ϫ High Fidelity Platinum PCR buffer, 2 mM MgSO 4 , 0.2 mM (each) deoxynucleoside triphosphates, 0.2 M (each) primers, and 0.025 U/l Platinum Taq high-fidelity polymerase were combined in a 20-l reaction mixture. cDNA was serially diluted until a concentration was found where PCR-positive wells constituted fewer than 30% of the total number of reaction wells. First-round PCR primers included the sense primer SIV-U5-F1 (5=-AGAAGTAAGCTAG TGTGTGTTCCCATCTCT-3=) and the antisense primer SIV-Gag-R1. PCR was performed by denaturation at 94°C for 1 min followed by 35 cycles of 94°C for 20 s, 55°C for 30 s, and 68°C for 1 min, and the reaction was terminated with a single 10-min extension at 68°C. Next, 1 l of each reaction mixture was transferred to a second-round reaction mixture that included the sense primer SIV-U5-F2 (5=-AGCTAGTGTGTGTTCCCAT CTCTCCTA-3=) and the antisense primer SIV-Gag-R2 (5=-CCAAAGAG AGAATTGAGGTGCAG-3=). The second-round PCR was performed under the same PCR conditions, but for 45 cycles. All PCR procedures were performed under PCR clean room conditions and using procedural safeguards against sample contamination, including prealiquoting of all reagents, use of dedicated equipment, and physical separation of sample processing from pre-and post-PCR amplification steps. Correctly sized amplicons, as determined by electrophoresis on an agarose gel, were directly sequenced by cycle sequencing using BigDye Terminator chemistry and protocols recommended by the manufacturer (Applied Biosystems). Individual sequence fragments for each amplicon were assembled and edited using Sequencher (Gene Codes).
qPCR assay design and validation. Based on the sequences determined as described above, the quantitative PCR (qPCR) assay primers and probe were designed to accommodate the SIV smm variation identified by this sequence analysis through the introduction of the nonstandard bases P and K (Gen Research) and degenerate bases (IDT). The newly designed assay consisted of the forward primer smGAGf (5=-GTCTGCG TCATTTGGTGCATPC-3=), the reverse primer smGAGr (5=-CACTAGA TGTCTCTGPACTAT/GTTGTTTTG-3=), and the probe smGAGp (5=-6carboxyfluorescein [FAM]-CTTCPTCAGTKTGTTTCACTTTCTCTTC TGCG-BHQTM1-3=). Assay validation was performed on a mixture of in vitro transcripts generated individually from the 6 dominant variant templates, providing coverage of 96% of the 299 sequences obtained. The assay was optimized for a maximal sensitivity of specific target detection of eight copy equivalents per reaction mix (95% assurance).
Quantitative analysis of SIV smm RNA samples by SM-specific RT-PCR assay. SIV smm RNA isolation from cell-free sooty mangabey plasma samples was performed as previously described (32) . Quantitative assessment of SIV smm RNA was determined by a quantitative hybrid real-time/ digital RT-PCR approach, which was modified from the plasma viral detection assay as described previously (33) . The cDNA reaction mixtures were reduced to 15 l, comprising 5 l sample plus 10 l concentrated reaction cocktail, and contained 5 ng/l random hexamers, 5 U RNaseOUT RNase inhibitor (Invitrogen), and 10 U SuperScript III reverse transcriptase (Invitrogen). Twelve replicate reactions were performed per sample. Quantitative determinations for samples showing amplification in all replicates were derived by interpolation of the averaged threshold cycle (C T ) value for the reactions onto a standard curve of C T versus input template copy number. Quantitative determinations for samples showing fewer than 12 positive amplifications in replicates were derived from the frequency of positive amplifications, corresponding to the presence of at least one target copy in a reaction mixture, according to a Poisson distribution of a given median copy number per reaction mixture. The assay yielded no positive reactions for a total of 72 total reaction mixtures for RNA samples derived from 6 uninfected animals.
Memory CD4 ؉ T cell subset sorting. Enriched unlabeled CD4 ϩ T cells were obtained by magnetic bead isolation and passage through a magnetically activated cell sorting (MACS) selection column placed in a MACS separator (Miltenyi, Auburn, CA). Cells in suspension were stained with the proper antibody mixture and then physically separated by fluorescence-activated cell sorting (FACS). Sorting of CD4 ϩ T EM , T CM , T TM , and T SCM cells based on the expression of CD45RA, CCR7, CD28, CD95, and CD62L was performed on a FACS Aria II flow cytometer (BD Biosciences) for samples collected before and during ART. Cells were initially gated on the basis of light scatter, followed by positive staining for CD3 and CD4 and negative staining for the LIVE/DEAD fixable dead cell stain (Invitrogen, Carlsbad, CA).
Detection of cell-associated SIV DNA. Sorted CD4 ϩ T cell subsets were lysed and homogenized in a highly denaturing guanidine isothiocyanate-containing buffer which inactivates DNases and RNase and disrupts cell membranes. Total DNA was then extracted by use of an AllPrep DNA/ RNA minikit (Qiagen) according to the manufacturer's recommendations. Quantitative assessments of cell-associated total SIV DNA within circulating memory CD4 ϩ T cell subsets at day Ϫ30 pre-ART administration and days 45, 184, 274, and 365 on ART were performed by real-time PCR. Briefly, 45 ng of DNA was loaded into a 50-l reaction mixture with an SIVutr primer/probe set. The same SIV-specific primers and probe were used to amplify and quantify total provirus copies of SIV as described before. Albumin was used as an internal control to quantify the cell number against an external standard curve. An albumin gene-specific probe (5=-VIC-TGACAGAGTCACCAAATGCTGCACAGAA-3=) and flanking primers (5=-TGCATGAGAAAACGCCAGTAA-3= and 5=-ATGGTCGCC TGTTCACCAA-3=) (Applied Biosystems) were used to determine the proportion of SIV DNA ϩ cells by dividing the obtained SIV DNA copy number by the albumin gene copy number (5) .
Statistical analysis. Comparisons between circulating CD4 ϩ T cell, CD4 ϩ T cell subset, and CD8 ϩ T cell frequencies and absolute counts pre-ART and during ART were carried out using the nonparametric Wilcoxon matched-pair signed-rank test. The same analysis was carried out for mucosal populations as well. Comparisons between the levels of expression of different markers on CD4 ϩ and CD8 ϩ lymphocyte popula-tions and their subsets were determined for points during ART versus previous time points and the baseline. Specifically, the unpaired t test, the unpaired t test with Welch's correction, and the nonparametric Wilcoxon matched-pair signed-rank test were carried out. Variations between preand on-ART cell-associated virus (SIV DNA) levels in SM blood were monitored over time, and statistical significance was determined using repeated-measure analyses of each CD4 T cell subset (SAS MIXED Procedure, version 9.4). The means Ϯ standard errors of the means (SEM) were used as descriptive statistics throughout the course of the study after ART initiation. In all cases, significance was attributed for P values of Ͻ0.05. All analyses were conducted using GraphPad Prism 5.0d and SAS MIXED Procedure, version 9.4.
RESULTS

Experimental design and baseline virological and immunological features of chronically SIV-infected SMs.
To assess directly the effects of virus replication on the immunological parameters of interest during chronic SIV infection of SMs, we used a potent four-drug ART regimen that was shown to be very effective at suppressing SIV replication in rhesus macaques (19) (20) (21) (22) . Twelve SIV-infected SMs were included in this study and were divided into four groups, each with three animals receiving ART for 2, 6, 9, or 12 months. On day 0 of the study (Fig. 1A) , all animals were treated with PMPA (20 mg/kg/day), FTC (30 mg/kg/day), DRV (400 mg b.i.d.), and RAL (150 mg b.i.d.). Blood and rectal biopsy (RB) specimens were collected longitudinally throughout the course of the study, as shown in Fig. 1A , to monitor a number of virological and immunological parameters prior to and during ART and after ART interruption. After ART interruption, all SIV-infected SMs were monitored for at least 2 months and up to 6 months (Fig. 1A) . The 12 SIV-infected SMs included in this study were selected from the colony of animals housed at the YNPRC, and their basic immunological and virological features are shown in Fig. 1B , with viral loads ranging from 1,940 to 261,000 copies/ml of plasma and CD4 ϩ T cell counts ranging from 167 to 1,336 cells/mm 3 of blood. Note that, for this study, we selected animals that were not homozygous for the previously described CCR5-null genes (34) .
ART is well tolerated and induces potent suppression of virus replication in chronically SIV-infected SMs. To investigate the effect of ART on the main virological and immunological pa- rameters of SIV infection, the 12 SIV-infected SMs received ART for different periods (60, 184, 274, or 365 days). Overall, ART was safe and well tolerated by the majority of SIV-infected SMs that were included in this study. Two animals (FUv and FJy) exhibited a moderate weight loss that was reversed with diet supplementation, with a rapid return to baseline weight after ART interruption. The 21-year-old animal FWo, which was originally included in the 2-month treatment group, was euthanized on day 43 of therapy due to major cardiovascular symptoms that were attributed to aging by the YNPRC veterinary staff. As expected, all ani-mals receiving ART experienced a rapid and significant decline in plasma viral load ( Fig. 2A , gray boxed areas of the graphs). As shown in Fig. 2A , 6 of 11 SIV-infected SMs showed viremia suppression to below the level of detection of our standard SIV smm viral load assay (i.e., 60 copies/ml) by day 30 after ART initiation, and the viral loads of four other animals became undetectable by day 45 of treatment. Only one animal (FSs) exhibited relative resistance to ART, with a viral load that declined but remained detectable after 184 days of ART. To further investigate the level of ART-induced virus suppression in SIV-infected SMs that had un- detectable viral loads with our standard assay, we next measured viremia by using an ultrasensitive SIV smm -specific RT-PCR assay with a limit of detection of 10 copies/ml. The results of this ultrasensitive assay indicated that low levels of virus production were still present in all ART-treated SIV-infected SMs, though it remains unclear whether this production was related to de novo cycles of virus replication versus persistent virus production in cells that were infected prior to ART (data not shown).
ART induces modest changes in the level of SIV DNA in memory CD4 ؉ T cell subsets. In previous studies, we showed that nonpathogenic SIV infection of SMs is associated with lower levels of infection (as measured by total cell-associated SIV DNA) in CD4 ϩ T CM and T SCM cells than those seen with pathogenic SIV infection of RMs (4) (5) (6) . To investigate the effects of ART on the levels of SIV infection in different memory CD4 ϩ T cell subsets, we identified and sorted T SCM , T CM , T TM , and T EM cells based on the surface expression of CD45RA, CD62L, CCR7, CD28, and CD95 and quantified the levels of total SIV DNA by RT-PCR for samples collected at various time points during the study (i.e., day 30 pre-ART and days 60, 184, 274, and 365 on ART). As shown in Fig. 3A , a significant decrease in SIV DNA content was detected in the T EM CD4 ϩ T cell subset (P ϭ 0.02) as a result of ART-mediated suppression of virus replication in this subset of short-lived cells.
However, we found no statistically significant trends in infection of the other examined CD4 T cell subsets, i.e., T TM , T CM , and T SCM cells (average changes of 0.9-, 1.1-, and 3.7-fold for CD4 T TM , T CM , and T SCM cells, respectively). Note that one SIV-infected SM (FEz) exhibited undetectable levels of SIV gag copies in T SCM and T CM fractions both prior to ART treatment and during treatment. However, the apparent absence of SIV infection in these two longlived memory CD4 ϩ T cell compartments was not sufficient to avoid rapid viral rebound once ART was stopped (Fig. 2B) . Overall, these data indicate that administration of suppressive ART for 2 to 12 months induced a significant decline in the level of cellassociated SIV DNA in circulating CD4 ϩ T EM cells but had little impact on any of the other memory CD4 T cell subsets.
ART induces a significant repopulation of peripheral CD4 ؉ T CM cells and total intestinal CD4 ؉ T cells in SIV-infected SMs.
In HIV-infected humans, initiation of ART induces a series of immunological changes, including a rapid increase in peripheral CD4 ϩ T cell counts as well as a slower and incomplete reconstitution of the mucosal CD4 ϩ T cell pool (13, (35) (36) (37) (38) (39) . To evaluate the impact of ART-induced suppression of virus replication on CD4 ϩ T cell reconstitution, we next measured, for our cohort of ARTtreated SIV-infected SMs, the levels of CD4 ϩ T cells in peripheral blood (PB) and rectal biopsy (RB) specimens taken at several time points during the study. As shown in Fig. 4A , we found that the number of circulating CD4 ϩ T cells remained stable during ART, with most animals experiencing only minor fluctuations. We next investigated how ART influenced the dynamics of the subsets of T N , T SCM , T CM , T TM , and T EM CD4 ϩ T cells in peripheral blood. As shown in Fig. 4B , we found that the percentages of CD4 ϩ T N , T SCM , and T TM cells remained relatively constant after ART in our cohort of SIV-infected SMs, with only minor fluctuations observed in some animals. In contrast, ART-treated SIV-infected SMs showed a significant expansion of CD4 ϩ T CM cells on days 45, 92, and 135 post-ART compared to baseline pre-ART levels (for day Ϫ30 versus day 45, P ϭ 0.0039; for day Ϫ30 versus day 92, P ϭ 0.0039; and for day Ϫ30 versus day 135, P ϭ 0.0177) that was associated with a concomitant decline of CD4 ϩ T EM cells on days 75 and 120 post-ART (for day Ϫ30 versus day 75, P ϭ 0.0039; and for day Ϫ30 versus day 120, P ϭ 0.0039). Note that the ARTinduced increase in peripheral CD4 ϩ T CM cells persisted on day 60 after ART interruption (Fig. 4B , day Ϫ30 versus day 60) (P ϭ 0.0064). As shown in Fig. 4C , the analysis of CD4 ϩ T cells in RB specimens (measured as the fraction of CD3 ϩ T cells) from ARTtreated SIV-infected SMs showed a significant increase compared to pre-ART levels (for day Ϫ30 versus day 92, P ϭ 0.0391; and for day Ϫ30 versus day 135, P ϭ 0.0117) (Fig. 4C) . Interestingly, the observed increase of CD4 ϩ T cells in RB specimens was not reversed once ART was interrupted, with the percentage of CD4 ϩ T cells in the rectal mucosa at day 60 post-ART interruption remain- ing higher than that at baseline (i.e., pre-ART) (Fig. 4C ). Overall, these data indicate that ART induced a significant immune reconstitution in SIV-infected SMs, with increases in both peripheral CD4 ϩ T CM and mucosal CD4 ϩ T cells.
ART reduces the levels of activated CD8 ؉ T cells in the peripheral blood and rectal mucosa of SIV-infected SMs. In HIVinfected humans, initiation of ART induces a reduction in the expression of activation and proliferation markers on CD4 ϩ and CD8 ϩ T cells in peripheral blood as well as on lymphoid and mucosal tissues (13, (35) (36) (37) (38) (39) . To characterize the impact of ART on the levels of immune activation of SIV-infected SMs, we next longitudinally assessed the expression of HLA-DR, PD-1, and Ki-67, i.e., three key markers of T cell activation (HLA-DR and PD-1) and proliferation (Ki-67), on CD4 ϩ and CD8 ϩ T cells from peripheral blood and rectal biopsy specimens. As expected based on previous studies, SIV-infected SMs showed relatively low levels of CD4 ϩ and CD8 ϩ T cell activation before ART. As shown in Fig.  5A , ART did not induce any change in the levels of CD4 ϩ HLA-DR ϩ T cells in either the peripheral blood or the rectal mucosa. In contrast, we found that the percentage of CD8 ϩ HLA-DR ϩ T cells declined significantly at day 135 of ART in peripheral blood (for day Ϫ30 versus day 135, P ϭ 0.0039) and at day 92 of ART in RB specimens (for day Ϫ30 versus day 92, P ϭ 0.0078) compared to the baseline (pre-ART) levels. Interestingly, ART interruption was followed by an increase of the percentage of CD8 ϩ HLA-DR ϩ T cells in both blood and RB specimens (for PB at day Ϫ30 versus day 30, P ϭ 0.0163; for PB at day 135 versus day 30, P ϭ 0.0039; for PB at day Ϫ30 versus day 45, P ϭ n.s. [not significant]; for PB at day 135 versus day 45, P ϭ 0.0078; for RB specimens at day Ϫ30 versus day 106, P ϭ n.s.; and for RB specimens at day 92 versus day 106, P ϭ 0.0078) (Fig. 5B) . No significant changes were found in the level of either PD-1 ϩ or Ki-67 ϩ T cells (either CD4 ϩ or CD8 ϩ ) in peripheral blood or rectal mucosa of ART-treated SIV-infected SMs (data not shown). Overall, these data suggest that ART is followed by a decline of CD8 ϩ (but not CD4 ϩ ) T cell activation that returns to pre-ART levels upon ART interruption.
ART interruption is followed by rapid virus rebound in SIVinfected SMs. Interruption of ART is followed by a rapid (i.e., within weeks) rebound of viremia in HIV-infected individuals, with numerous studies suggesting that virus persistence under ART is related to the latent infection of long-lived, resting memory CD4 ϩ T cells, mainly belonging to the T CM and T SCM subsets (4, 5, (40) (41) (42) (43) . In our cohort of ART-treated SIV-infected SMs, we interrupted ART at various time points after initiation (see above for details) and measured the level of plasma viremia longitudinally. As shown in Fig. 2B , we found that regardless of the duration of ART (ranging from 2 to 12 months), all SIV-infected SMs experienced a rapid rebound of virus replication. In most animals, the kinetics of virus rebound after ART interruption showed a peak of viremia at approximately day 30 postinterruption that then stabilized at slightly lower levels (decline of 0.5 to 1 log) in the following weeks (i.e., similar to the pre-ART set-point viremia). These results indicate that a reservoir of SIV-infected cells that harbor replication-competent virus clearly remain present in SMs under ART for up to 1 year, despite lower levels of infection in CD4 ϩ T CM and T SCM cells.
DISCUSSION
Natural SIV infection of SMs is typically nonpathogenic despite high levels of virus replication and the short in vivo life span of productively infected cells (26) . A series of studies indicated that the main mechanisms of protection from SIV disease progression in these animals are the lack of aberrant immune activation during the chronic phase of the infection, preservation of Th17 cells and mucosal integrity, and the preferential sparing of CD4 ϩ T CM and T SCM cells from direct virus infection (4, 5, 41, 42) . None of these published studies involved prolonged administration of potent, multidrug antiretroviral regimens, with only one study in which PMPA and FTC were used for a relatively short period as an experimental tool to assess the in vivo life span of productively infected cells (26) . The main findings of the current study are that administration of ART in SIV-infected SMs was well tolerated overall and resulted in a rapid decline of viremia to levels below the limit of detection of our standard assay in all but one treated animal. The level of viremia decline observed in the current study is comparable overall to what we observed in similar studies conducted on SIV-infected RMs (19, 44) . In addition, we found that ART initiation was followed by an increase in the percentage of CD4 ϩ T CM cells in peripheral blood, an increase of CD4 ϩ T cells in the rectal mucosa, and a decline in the levels of activated CD8 ϩ HLA-DR ϩ T cells in both blood and the rectum. Finally, we found that ART interruption resulted in rapid viral rebound in all treated animals.
The lower levels of infection in the long-lived CD4 ϩ T SCM and T CM cells of SIV-infected SMs suggested that the reservoir is possibly less stable under ART. While the current study does not directly support this hypothesis, there are several arguments against the conclusion that limited CD4 ϩ T SCM and T CM cell infection does not affect virus persistence in this model. These arguments include the following: (i) residual viremia was detected in all treated animals (using an ultrasensitive viral load assay that cannot distinguish, however, between rounds of de novo virus replication and residual virus production from cells infected prior to ART), (ii) the reservoir was measured only in peripheral blood, (iii) SIV DNA levels were low but still detectable in CD4 ϩ T CM and T SCM cells in the majority of SIV-infected SMs, and (iv) ART was used for a period of 2 to 12 months only. An additional caveat is that this study included several SMs that were infected intravenously with SIV, while most of the naturally SIV-infected animals contracted the infection through sexual intercourse. All these caveats notwithstanding, we found it interesting that virus rebound was also observed in one SIV-infected SM with undetectable SIV DNA in both CD4 ϩ T CM and T SCM cells (but still with detectable plasma viremia as measured by the ultrasensitive viral load assay). Future studies involving long-term ART (i.e., Ͼ2 years) and in which ART interruption is performed only when the treated SIV-infected SMs show undetectable viremia by the most sensitive assay (i.e., with quasispecies-specific probes and a limit of detection of 3 copies/ml of plasma) will be necessary to ascertain if, under those conditions, the virus reservoir may indeed prove to be less stable as a consequence of the lower infection levels of CD4 ϩ T CM and T SCM cells.
An interesting and perhaps unexpected finding of this study is that ART had a positive impact on CD4 ϩ T cell reconstitution in SIV-infected SMs, as revealed by significant increases of both total CD4 ϩ T cells in the rectal mucosa and CD4 ϩ T CM cells in peripheral blood. While SIV infection of SMs is typically nonpathogenic, with infected animals experiencing a life span similar to that of uninfected animals (10), the infection is not devoid of some immunological abnormalities. In particular, we have shown that SIV-infected SMs experience a significant decline of CD4 ϩ T cells in mucosal tissues (9) , even though this decline is not progressive after the acute phase of infection, does not reach the nadirs often observed in pathogenic HIV and SIV infections, and is not associated with a loss of mucosal integrity or detectable microbial translocation (8, 9, 45) . In this study, we observed, for the first time, that suppression of virus replication with ART induces a significant increase in the level of CD4 ϩ T cells in the rectum and that this increase compared to pre-ART values persists even after ART interruption. This observation contrasts with the relatively slow and partial effect of ART in normalizing the levels of mucosal CD4 ϩ T cells in humans. It is tempting to speculate that in SIVinfected SMs, the low levels of immune activation as well as the preservation of Th17 cells and mucosal immunity may favor the recovery of mucosal CD4 ϩ T cells when virus replication is controlled by ART.
The observed impact of ART on the levels of circulating CD4 ϩ T CM cells as well as the levels of CD8 ϩ T cells expressing the activation marker HLA-DR may also indicate that subtle immunological changes induced by persistent virus replication are present in SIV-infected SMs. The affected processes include CD4 ϩ T cell homeostasis, which is largely dependent on the presence of healthy levels of T CM cells in blood and tissues (46) , and CD8 ϩ T cell activation. The reasons for these changes not translating into a major immunological dysfunction with associated clinical signs of opportunistic infections remain unknown. However, in this regard, the current study opens up new avenues of research aimed at investigating what additional mechanisms may operate in SIVinfected SMs to limit the clinical impact of the immune abnormalities that are revealed and reversed by ART administration.
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